Comparative study between Intrastromal Injection of autologous blood and C3F8 Injection for treatment of Corneal Hydrops
Not Applicable
Recruiting
- Conditions
- Corneal EdemaC11.204
- Registration Number
- RBR-109k3fmj
- Lead Sponsor
- niversidade Federal de São Paulo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients older than ten years of age; both genders; patients who were clinically diagnosed with Acute Corneal Hydrops; patients who signed the medical consent term; availability for all the study visits
Exclusion Criteria
Having been submitted to ocular surgery in the last six months; presenting Hydrops condition for more than two months; occurrence or suspicion of occurrence of infectious episodes on the ocular surface; presence of Corneal Perforation or Atalamia
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected the use of autologous blood to be safer, presenting less cost and discomfort to the patient when compared to the use of C3F8, such as verified by ambulatorial clinical evaluations, from which fewer complications and symptoms were observed.
- Secondary Outcome Measures
Name Time Method Autologous blood intrastromal injection and C3F8 intracameral injection will accelerate the resolution of the acute corneal hydrops condition, as verified by clinical evaluation and by diagnostic imaging, such as Optical Coherence Tomography, identifying reduction of the corneal edema and the appearance of corneal scaring free of complications.